Regeneron (REGN) Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the supplemental biologics license application for the addition of extended dosing intervals for Eylea HD injection 8 mg across all approved indications. “The CRL did not identify any issues with the safety or efficacy of Eylea HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron’s proposal to add additional extended dosing intervals (greater than every 16 weeks, which is the maximum dosing interval currently indicated in the label). Regeneron is evaluating the FDA’s decision and will determine a path forward in due course,” the company said in a statement. Eylea HD is approved with dosing intervals from every 8 to 16 weeks for patients with wet age-related macular degeneration and diabetic macular edema, and every 8 to 12 weeks for patients with diabetic retinopathy, following three initial monthly doses. Shares of Regeneron are down 1% to $556.64 in morning trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD
- Regeneron, Sanofi announce FDA approval of Dupixent for CSU
- Regeneron announces FDA accepted Priority Review sBLA for EYELEA HD
- Regeneron price target lowered to $150 from $170 at Canaccord
- Regeneron price target lowered to $547 from $575 at BofA